DNA, Drugs and Genome Project - Clinical Research Informer

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. In actuality, the protein-coding portion of our genome is comparable in identity and number with the humble fruit fly or worm.

RNA

RNA Genome Genomics DNA

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

JANUARY 26, 2023

In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA. Understanding individual drug reactions and metabolism Pharmacogenomics is emerging as an important area.

Genome

Genome Genomics Genome Project Genetics

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs

Drugs Life Science Gene Therapy Genome

Genomic projects exploit scale as clinical applications play catch-up

Pharmaceutical Technology

JUNE 30, 2022

In a Nature publication , Florian Markowetz, PhD, and his fellow researchers analyzed copy number signatures across a number of cancers, and found 17 types of chromosomal instability while identifying 49 new drug targets. Space for discovery, development, and repurposing of drugs. Both teams had the same underlying goal.

Genome Project

Genome Project Genome Genomics DNA

Patients of African heritage have fewer actionable mutations

Drug Discovery World

APRIL 17, 2023

Genetic sequencing To assess these alterations in groups of different ancestries, Walch and colleagues analysed targeted DNA sequencing data from 4,441 patients treated for colorectal cancer at MSK between 2014 and 2022. Genetic ancestry was estimated using reference populations from the 1000 Genomes Project.

Genome

Genome Genomics Gene Sequencing Genome Project

Personalising whole genome sequencing doubles diagnosis of rare diseases

Drug Discovery World

NOVEMBER 7, 2022

They subsequently applied additional bioinformatic approaches, using advanced computer technologies to identify genetic alterations in a patients’ DNA which may be causing disease but had been overlooked during routine testing. . It can also permit targeted screening of known disease complications and access to drug studies.

Genome

Genome Genomics Genetics Genetic Disease

Why genomic healthcare data matters in the development of new therapies

Drug Discovery World

NOVEMBER 7, 2022

One might argue that this all started getting exciting with the launch of the Human Genome Project, which the National Human Genome Research Institute consider to be one of the greatest scientific feats in history 1. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact. .

Genome

Genome Genomics Development Genetics

Q&A: Gene therapy opportunities from long-read sequencing

Drug Discovery World

SEPTEMBER 20, 2022

The key difference between the two technologies is that long-read sequences are more effective at unambiguously determining how all the pieces of a sequenced genome fit together. Cancer is a disease of the genome, and the more we can understand cancer at a molecular level, the quicker we can make diagnoses and better treat people.

Gene Therapy

Gene Therapy Gene Genome Genomics

Bioinformatics Jobs: How to Succeed in This Competitive Space

XTalks

APRIL 5, 2021

The Human Genome Project could not have succeeded without the use of bioinformatics. Since the conclusion of the project in 2003, bioinformatics tools have been used to identify genes and elucidate their function with the aim of developing gene-based strategies for disease prevention, diagnosis and treatment.

Bioinformatics

Bioinformatics Engineer Scientist Genome

A history of blood cancer treatment

pharmaphorum

SEPTEMBER 13, 2022

Just over a decade after it was developed by biochemist Nicholas Lyndon, Imatinib received US Food and Drug Administration (FDA) approval in 2001. 2012 – The 100,000 Genomics Project begins. Unlocking the secrets of the human genome has intrigued investigators for centuries. 2002 – Emergence of CAR-T therapy.

Genome Project

Genome Project Genome Genomics DNA

CRISPR therapies targeting the next breakthrough in oncology

pharmaphorum

APRIL 20, 2022

In 2012, Jennifer Doudna and Emmanuelle Charpentier published a paper in Science where they outlined isolating the components of the CRISPR-Cas9 system and demonstrated how it could be used to cut specific sites in isolated DNA. The publication and their work eventually led to the pair being awarded the Nobel Prize in Chemistry in 2020.

Gene Editing

Gene Editing DNA Gene Genetics

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

SEPTEMBER 14, 2020

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. Now, however, the field is changing with respect to genomic medicine. On one hand, unfortunately this means that many drugs are doomed to failure. This allows for much lengthier reads.

Genome

Genome Genomics Medicine Gene

The era of precision neuroscience

Drug Discovery World

MARCH 6, 2024

To find new ways of diagnosing and treating complex diseases we first must understand the mechanisms underpinning their key pathological drivers, how these relate to different patient subgroups, and which drugs might be useful in ameliorating their effects – this is the basis of precision neuroscience. This is wholly unsurprising.

Genome

Genome Genomics Clinical Trials Clinical Trials

Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. For more details on this emerging domain, check out the following report : SPATIAL GENOMICS MARKET.

Genome

Genome Genomics RNA Genome Project

Predictive diagnostics: closing the precision medicine gap

Drug Discovery World

OCTOBER 6, 2022

In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies. In pursuit of this, the number of new therapeutics in development has boomed.

Medicine

Medicine Clinical Trials Clinical Trials Genome

Clinical Research Informer

Junk DNA: How the dark genome is changing RNA therapies

A new dawn of the genomic age: five areas set to be transformed in 2023

Trending Sources

Where is the drug discovery expertise happening in the UK?

Genomic projects exploit scale as clinical applications play catch-up

Patients of African heritage have fewer actionable mutations

Personalising whole genome sequencing doubles diagnosis of rare diseases

Why genomic healthcare data matters in the development of new therapies

Q&A: Gene therapy opportunities from long-read sequencing

Bioinformatics Jobs: How to Succeed in This Competitive Space

A history of blood cancer treatment

CRISPR therapies targeting the next breakthrough in oncology

The future of genomic medicine: can it fulfil its promises?

The era of precision neuroscience

Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics

Predictive diagnostics: closing the precision medicine gap

Stay Connected